Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia?
J. M. Schenk, Rachel A. Hunter‐Merrill, Yingye Zheng et al. · American Journal of Epidemiology · 2013
Although surrogate measures of benign prostatic hyperplasia (BPH) are often used in epidemiologic studies, their performance characteristics are unknown. Using data from the Prostate Cancer Prevention Trial (n = 5,986), we evaluated prostate-specific antigen (PSA), International Prostate Symptom Score (IPSS), and their rates of change as predictors of incident BPH. BPH (n = 842 cases) was defined as medical or surgical treatment or at least 2 IPSS of 15 or higher. Proportional hazards models were used to measure the associations of baseline PSA, IPSS, and their velocities over 2 years with BPH risk, and time-dependent receiver-operating characteristic curves were used to measure their discriminatory performance. Unit increases in PSA, IPSS, and IPSS velocity were associated with 34%, 35%, and 29% (all P < 0.001) increases in BPH risk, respectively. The areas under the receiver-operating characteristic curves were significantly greater than 0.5 for PSA (0.58, 95% confidence interval (CI): 0.56, 0.60), IPSS (0.77, 95% CI: 0.75, 0.78), and IPSS velocity (0.63, 95% CI: 0.61, 0.65); however there were no cut points at which sensitivity and specificity were both above 75%. We concluded that moderate elevations in PSA, IPSS, or their rates of change should not be used as surrogate measures of incident BPH.
Cited by 3 works. doi:10.1093/aje/kwt044
Authors
- J. M. Schenk
- Rachel A. Hunter‐Merrill
- Yingye Zheng
- Ruth Etzioni
- R. Gulati
- Catherine M. Tangen
- Ian Murchie Thompson
- Alan R. Kristal
References
- The Analysis of Failure Times in the Presence of Competing Risks
- The Influence of Finasteride on the Development of Prostate Cancer
- The Influence of Finasteride on the Development of Prostate Cancer
- High prevalence of benign prostatic hypertrophy in the community
- AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations
- UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN PROSTATIC HYPERPLASIA
- Correlation of the American Urological Association Symptom Index with Self-Administered Versions of the Madsen-Iversen, Boyarsky And Maine Medical Assessment Program Symptom Indexes
- Natural history of benign prostatic hyperplasia
- Risk Factors for Lower Urinary Tract Symptoms in a Population-based Sample of African-American Men
- Race/Ethnicity, Obesity, Health Related Behaviors and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial